Activation of KIF4A as a prognostic biomarker and therapeutic target for lung cancer

Clinical Cancer Research

Volumn 13, Issue 22, 2007, Pages 6624-6631

  Taniwaki, Masaya ^a,b   Takano, Atsushi ^a   Ishikawa, Nobuhisa ^a   Yasui, Wataru ^b   Inai, Kouki ^b   Nishimura, Hitoshi ^c   Tsuchiya, Eiju ^d   Kohno, Nobuoki ^b   Nakamura, Yusuke ^a   Daigo, Yataro ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

^c SAITAMA CANCER CENTER   (Japan)

^d KANAGAWA CANCER CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; COMPLEMENTARY DNA; KINESIN; KINESIN FAMILY MEMBER 4A; MATRIGEL; PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER SURVIVAL; CANCER THERAPY; CELL INVASION; CONTROLLED STUDY; DNA MICROARRAY; FEMALE; GENE; GENETIC SCREENING; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MAMMAL CELL; MULTIVARIATE ANALYSIS; PATHOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN TARGETING; STATISTICAL SIGNIFICANCE; TISSUE MICROARRAY;

AGED; ANTINEOPLASTIC AGENTS; CANCER VACCINES; CARCINOMA, NON-SMALL-CELL LUNG; CELL PROLIFERATION; DRUG DESIGN; FEMALE; HUMANS; KINESIN; LUNG NEOPLASMS; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; RNA, SMALL INTERFERING; TRANS-ACTIVATION (GENETICS); TUMOR MARKERS, BIOLOGICAL;

EID: 36749076543     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-1328     Document Type: Article

References (46)

1. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin 2001;51:15-36.
2. Sozzi G. Molecular biology of lung cancer. Eur J Cancer 2001;37 Suppl 7:S63-73.
3. Morita T, Sugano H. A statistical analysis of lung cancer registered in the Annual of Pathological Autopsy Cases in Japan between 1958 and 1987, with special reference to the characteristics of lung cancer in Japan. Acta Pathol Jpn 1990;40:665-75.
4. Simon GR, Wagner H. Small cell lung cancer. Chest 2003;123 Suppl 1:S259-71.
5. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001;2:533-43.
6. Chute JP, Chen T, Feigal E, Simon R, Johnson BE. Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. J Clin Oncol 1999;17:1794-1801.
7. Sandler AB. Chemotherapy for small cell lung cancer. Semin Oncol 2003;30:9-25.
8. Kikuchi T, Daigo Y, Katagiri T, et al. Expression profiles of non-small cell lung cancers on cDNA microarrays: identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs. Oncogene 2003;22:2192-205.
9. Kakiuchi S, Daigo Y, Tsunoda T, Yano S, Sone S, Nakamura Y. Genome-wide analysis of organ-preferential metastasis of human small cell lung cancer in mice. Mol Cancer Res 2003;1:485-99.
10. Kakiuchi S, Daigo Y, Ishikawa N, et al. Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839). Hum Mol Genet 2004;13:3029-43.
11. Kikuchi T, Daigo Y, Ishikawa N, et al. Expression profiles of metastaticbr ain tumor from lung adenocarcinomas on cDNA microarray. Int J Oncol 2006;28:799-805.
12. Taniwaki M, Daigo Y, Ishikawa N, et al. Gene expression profiles of small-cell lung cancers: molecular signatures of lung cancer. Int J Oncol 2006;29:567-75.
13. Yamabuki T, Daigo Y, Kato T, et al. Genome-wide gene expression profile analysis of esophageal squamous-cell carcinomas. Int J Oncol 2006;28:1375-84.
14. Ochi K, Daigo Y, Katagiri T, et al. Prediction of response to neoadjuvant chemotherapy for osteosarcoma by gene-expression profiles. Int J Oncol 2004;24:647-55.
15. Saito-Hisaminato A, Katagiri T, Kakiuchi S, Nakamura T, Tsunoda T, Nakamura Y. Genome-wide profiling of gene expression in 29 normal human tissues with a cDNA microarray. DNA Res 2002;9:35-45.
16. Ochi K, Daigo Y, Katagiri T, et al. Expression profiles of two types of human knee joint cartilage. J Hum Genet 2003;48:177-82.
17. Suzuki C, Daigo Y, Kikuchi T, Katagiri T, Nakamura Y. Identification of COX17 as a therapeutic target for non-small cell lung cancer. Cancer Res 2003;63:7038-41.
18. Ishikawa N, Daigo Y, Yasui W, et al. ADAM8 as a novel serological and histochemical marker for lung cancer. Clin Cancer Res 2004;10:8363-70.
19. Kato T, Daigo Y, Hayama S, et al. A novel human tRNA-dihydrouridine synthase involved in pulmonary carcinogenesis. Cancer Res 2005;65:5638-46.
20. Furukawa C, Daigo Y, Ishikawa N, et al. Plakophilin 3 oncogene as prognosticmarker and therapeutic target for lung cancer. Cancer Res 2005;65:7102-10.
21. Ishikawa N, Daigo Y, Takano A, et al. Increases of amphiregulin and transforming growth factor-α in serum as predictors of poor response to gefitinib among patients with advanced non-small cell lung cancers. Cancer Res 2005;65:9176-84.
22. Suzuki C, Daigo Y, Ishikawa N, et al. ANLN plays a critical role in human lung carcinogenesis through the activation of RHOA and by involvement in the phosphoinositide 3-kinase/AKT pathway. Cancer Res 2005;65:11314-25.
23. Ishikawa N, Daigo Y, Takano A, et al. Characterization of SEZ6L2 cell-surface protein as a novel prognostic marker for lung cancer. Cancer Sci 2006;97:737-45.
24. Takahashi K, Furukawa C, Takano A, et al. The neuromedin u-growth hormone secretagogue receptor 1b/neurotensin receptor 1 oncogenic signaling pathway as a therapeutic target for lung cancer. Cancer Res 2006;66:9408-19.
25. Hayama S, Daigo Y, Kato T, et al. Activation of CDCA1-2, members of centromere protein complex, involved in pulmonary carcinogenesis. Cancer Res 2006;66:10339-48.
26. Kato T, Hayama S, Yamabuki Y, et al. Increased expression of insulin-like growth factor-II messenger RNA-binding protein 1is associated with tumor progression in patients with lung cancer. Clin Cancer Res 2007;13:434-42.
27. Suzuki C, Takahashi K, Hayama S, et al. Identific ation of Myc-associated protein with JmjC domain as a novel therapeutic target oncogene for lung cancer. Mol Cancer Ther 2007;6:542-551.
28. Yamabuki T, Takano A, Hayama S, et al. Dickkopf-1as a novel serologican d prognostic biomarker for lung and esophageal carcinomas. Cancer Res 2007;67:2517-25.
29. Hayama S, Daigo Y, Yamabuki T, et al. Phosphorylation and activation of cell division cycle associated 8 by aurora kinase B plays a significant role in human lung carcinogenesis. Cancer Res 2007;67:4113-22.
30. Kato T, Sato N, Hayama S, et al. Activation of HJURP (Holliday junction-recognizing protein) involved in the chromosomal stability and immortality of cancer cells. Cancer Res 2007;67:8544-53.
31. Zhu C, Jiang W. Cell cycle-dependent translocation of PRC1 on the spindle by Kif4 is essential for midzone formation and cytokinesis. Proc Nat Acad Sci U S A 2005;102:343-8.
32. Miki H, Okada Y, Hirokawa N. Analysis of the kinesin superfamily: insights into structure and function. Trends Cell Biol 2005;15:467-76.
33. Lee YM, Kim W. Association of human kinesin superfamily protein member 4 with BRCA2-associated factor 35. Biochem J 2003;374:497-503.
34. Narayan G, Bourdon V, Chaganti S, et al. Gene dosage alterations revealed by cDNA microarray analysis in cervical cancer: identification of candidate amplified and overexpressed genes. Genes Chromosomes Cancer 2007;46:373-84.
35. Chin SF, Daigo Y, Huang HE, et al. A simple and reliable pretreatment protocol facilitates fluorescent in situ hybridisation on tissue microarrays of paraffin wax embedded tumour samples. Mol Pathol 2003;56:275-9.
36. Callagy G, Cattaneo E, Daigo Y, et al. Molecular classification of breast carcinomas using tissue microarrays. Diagn Mol Pathol 2003;12:27-34.
37. Callagy G, Pharoah P, Chin SF, et al. Identification and validation of prognostic markers in breast cancer with the complementary use of array-CGH and tissue microarrays. J Pathol 2005;205:388-96.
38. Ranson M, Hammond LA, Ferry D, et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol 2002;20:2240-50.
39. Lawrence CJ, Dawe RK, Christie KR, et al. A standardized kinesin nomenclature. J Cell Biol 2004;167:19-22.
40. Midorikawa R, Takei Y, Hirokawa N. KIF4 motor regulates activity-dependent neuronal survival by suppressing PARP-1 enzymatic activity. Cell 2006;125:371-83.
41. Hirokawa N. Kinesin and dynein superfamily proteins and the mechanism of organelle transport. Science 1998;279:519-26.
42. Miki H, Setou M, Kaneshiro K, Hirokawa N. All kinesin superfamily protein, KIF, genes in mouse and human. Proc Natl Acad Sci USA 2001;98:7004-11.
43. Muller C, Gross D, Sarli V, et al. Inhibitors of kinesin Eg5: antiproliferative activity of monastrol analogues against human glioblastoma cells. Cancer Chemother Pharmacol 2007;59:157-64.
44. Koller E, Propp S, Zhang H, et al. Use of a chemically modified antisense oligonucleotide library to identify and validate Eg5 (kinesin-like1) as a target for antineoplastic drug development. Cancer Res 2006;66:2059-66.
45. Zhu C, Zhao J, Bibikova M, et al. Functional analysis of human microtubule-based motor proteins, the kinesins and dyneins, in mitosis/cytokinesis using RNA interference. Mol Biol Cell 2005;16:3187-99.
46. Mazumdar M, Sundareshan S, Misteli T. Human chromokinesin KIF4A functions in chromosome condensation and segregation. J Cell Biol 2004;166:613-20.